Inactive Instrument

ONCODESIGN

Equities

ALONC

FR0011766229

Biotechnology & Medical Research

Oncodesign Announces Unaudited Revenue Results for the Year Ended December 31, 2015

January 20, 2016 at 12:06 pm

Oncodesign announced unaudited revenue results for the year ended December 31, 2015. For the year, the company reported has reported a strong increase in its 2015 revenue. Total revenue was EUR 14.52 million against EUR 7.18 million a year ago.

Latest news about ONCODESIGN

Oncodesign Société Anonyme(ENXTPA:ALONC) dropped from Next Biotech Index	22-12-21	CI
Oncodesign Services Names Successors as Chairman/CEO Departs	22-10-19	MT
Oncodesign Services Shareholders Sell Majority Stake to Edmond de Rothschild Fund	22-10-19	MT
Oncodesign Precision Medicine to List Directly on Euronext Access + Paris	22-10-05	MT
Oncodesign Société Anonyme completed the Spin-Off of Oncodesign Precision Medicine Société anonyme.	22-10-04	CI
Oncodesign Société Anonyme completed the Spin-Off of Oncodesign Precision Medicine Société anonyme.	22-10-04	CI
Oncodesign Unit Gains Approval To List On Euronext Access + In Paris	22-09-29	MT
Oncodesign Société Anonyme agreed to Spin-Off Oncodesign Precision Medicine.	22-09-27	CI
Oncodesign Société Anonyme Announces Planned Separation of Its Two Business Areas	22-07-01	CI
Oncodesign Société Anonyme Reports Earnings Results for the Full Year Ended December 31, 2021	22-04-07	CI
Sengine Precision Medicine and Oncodesign Announce Collaboration Agreement for the Discovery of New Personalized Cancer Treatment for Aggressive and Untreatable Tumors	22-02-08	CI
Oncodesign Société Anonyme Reports Turnover Results for the Year Ended December 31, 2021	22-01-27	CI
Oncodesign Société Anonyme's Equity Buyback announced on February 15, 2021, has expired.	21-12-23	CI
Oncodesign Strengthens the Intellectual Property of ODS 101 in Treating Inflammatory Bowel Disease	21-11-04	CI
Oncodesign : Appoints Chief Development Officer	21-10-26	MT
Oncodesign Appoints Karine Lignel as Group Chief Development Officer	21-10-25	CI
Oncodesign : Starts R&D Deal with TiumBio for Fibrosis Drug Candidates	21-10-21	MT
Oncodesign and TiumBio Sign Collaboration Agreement for R&D of Fibrosis Drug Candidates	21-10-21	CI
Oncodesign Announces Unaudited Consolidated Sales Results for the Half Year Ended June 30, 2021	21-09-16	CI
Global markets live: AT&T, American Airlines, Biogen, Netflix, ABB...	21-07-22
Oncodesign Announces Unaudited Consolidated Turnover Results for the First Half of 2021	21-07-21	CI
Oncodesign Appoints Aline Aubertin as New Independent Director	21-07-05	CI
Oncodesign Announces a Strategic Collaboration Agreement with Covalab	21-06-28	CI
Global markets live: Siemens, BHP Group, Visa, JP Morgan Chase, Proximus...	21-06-24
Oncodesign Provides Update on Its Progress on RIPK2	21-06-24	CI

Chart ONCODESIGN

Duration

Period

More charts

Company Profile

ONCODESIGN specializes in preclinical pharmacological evaluation services of new cancer therapies on behalf of the pharmaceutical and biotechnological companies. The group also provides research and development of drugs and biomarkers primarily for the treatment of cancer. The group's activity is organized around 3 business units: - Service: discovery, identification and selection of new therapeutic targets in oncology; - Biotech: development of a portfolio of therapeutic and diagnostic projects alone or through partnerships; - Artificial Intelligence: development of a platform for selecting new therapeutic targets in oncology. 60.3% of sales are abroad.

Sector

Biotechnology & Medical Research

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
MODERNA, INC.	+25.83%	46.56B
LONZA GROUP AG	+45.38%	41.67B
IQVIA HOLDINGS INC.	+0.69%	41.16B
ALNYLAM PHARMACEUTICALS, INC.	+30.52%	32.4B
ICON PUBLIC LIMITED COMPANY	+22.30%	28.18B
CELLTRION, INC.	-6.35%	28.1B
UNITED THERAPEUTICS CORPORATION	+49.25%	14.52B
MEDPACE HOLDINGS, INC.	+49.18%	13.74B
BIO-TECHNE CORPORATION	+3.45%	12.17B

Other Biotechnology & Medical Research